209 related articles for article (PubMed ID: 37494485)
1. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
[TBL] [Abstract][Full Text] [Related]
2. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
[TBL] [Abstract][Full Text] [Related]
3. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies.
Davis CW; Kallweit U; Schwartz JC; Krahn LE; Vaughn B; Thorpy MJ
Sleep Med; 2021 May; 81():210-217. PubMed ID: 33721598
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
Bogan RK; Feldman N; Emsellem HA; Rosenberg R; Lu Y; Bream G; Khayrallah M; Lankford DA
Sleep Med; 2015 Sep; 16(9):1102-8. PubMed ID: 26298786
[TBL] [Abstract][Full Text] [Related]
9. Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals.
Evans R; Kimura H; Nakashima M; Ishikawa T; Yukitake H; Suzuki M; Hazel J; Faessel H; Wu J; Hang Y; Alexander R; Rosen L; Hartman DS; Ratti E
J Sleep Res; 2023 Oct; 32(5):e13878. PubMed ID: 36934366
[TBL] [Abstract][Full Text] [Related]
10. Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.
Watson NF; Davis CW; Zarycranski D; Vaughn B; Dayno JM; Dauvilliers Y; Schwartz JC
CNS Drugs; 2021 Dec; 35(12):1303-1315. PubMed ID: 34822113
[TBL] [Abstract][Full Text] [Related]
11. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
Black J; Swick T; Bogan R; Lai C; Carter LP
Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
14. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Black J; Houghton WC
Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
[TBL] [Abstract][Full Text] [Related]
15. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
Ruoff C; Swick TJ; Doekel R; Emsellem HA; Feldman NT; Rosenberg R; Bream G; Khayrallah MA; Lu Y; Black J
Sleep; 2016 Jul; 39(7):1379-87. PubMed ID: 27166238
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
Szabo ST; Hopkins SC; Lew R; Loebel A; Roth T; Koblan KS
Sleep Med; 2023 Jul; 107():202-211. PubMed ID: 37209427
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
18. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
19. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
20. Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
van der Heide A; van Schie MK; Lammers GJ; Dauvilliers Y; Arnulf I; Mayer G; Bassetti CL; Ding CL; Lehert P; van Dijk JG
Sleep; 2015 Jul; 38(7):1051-8. PubMed ID: 25902810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
